CH Biotech R&D Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 110.94 million compared to TWD 92.67 million a year ago. Net loss was TWD 43.55 million compared to TWD 28.84 million a year ago. Basic loss per share from continuing operations was TWD 0.45 compared to TWD 0.3 a year ago. Diluted loss per share from continuing operations was TWD 0.45 compared to TWD 0.3 a year ago.
For the nine months, sales was TWD 1,371.1 million compared to TWD 1,380.38 million a year ago. Net income was TWD 539.31 million compared to TWD 574.6 million a year ago. Basic earnings per share from continuing operations was TWD 5.56 compared to TWD 5.92 a year ago. Diluted earnings per share from continuing operations was TWD 5.45 compared to TWD 5.81 a year ago.